Search

Lenacapavir Regulatory Approval

Regulatory approvals, pending decisions, and appeals as of August 2025, including US Food and Drug Administration approval.

Where We Are Now with LEN for PrEP

The chaos in foreign assistance programs (including discontinuation of major PrEP programs), cuts in staffing and new demands on donor commitments will make decisions on the procurement of LEN for PrEP more complex and uncertain.

Global Health Watch: CDC leaders depart, updates in the AVAC v Department of State case on foreign aid

This week, political overreach that is destabilizing global health programs and policy was on full display with the political interference and departure of leaders at the US Centers for Disease Control and Prevention (CDC) and the US Administration’s emergency appeal to the Supreme Court in AVAC v. Department of State case.

Reprioritization of Global Fund Programs: What it means  for Community actors in Malaria, Tuberculosis and HIV

AVAC Responds to Government’s Emergency Appeal to SCOTUS

In response to the US government’s August 26 emergency application to the US Supreme Court seeking to stay the preliminary injunction in the AVAC v Department of State legal case against the foreign aid freeze, AVAC’s Executive Director, Mitchell Warren, asks whether SCOTUS will restore some of the checks and balances this administration is consistently undermining.

AVAC Responds to Government’s Emergency Appeal to SCOTUS

In response to the US government’s August 26 emergency application to the US Supreme Court seeking to stay the preliminary injunction in the AVAC v Department of State legal case against the foreign aid freeze, AVAC’s Executive Director, Mitchell Warren, asks whether SCOTUS will restore some of the checks and balances this administration is consistently undermining.

Global Advocates Welcome the Launch of Merck’s EXPrESSIVE Program

Known as the EXPrESSIVE program, the drug maker Merck has two trials testing a monthly pill for PrEP. Merck is committed to stakeholder engagement, putting global advocates at the forefront of planning for the program. Numerous organizations and advocates commend Merck’s dedication to hearing from the community and shared this statement.

IMPT LET’s Talk MPTs “Introducing the Dual Prevention Pill: Lessons Learned and What’s Next for Regulatory, Research, and Rollout” Webinar

The EXPrESSIVE Trials Test a Monthly Pill for PrEP: Advocates speak

The drug maker Merck’s recent announcement of two new efficacy trials of a monthly PrEP pill, known as the EXPrESSIVE program, is welcome news. In addition, Merck’s robust commitment to stakeholder engagement to date contributes an important model of Good Participatory Practice (GPP) to the field, by putting global advocates at the forefront of planning for the program.

Key Messages from IAS 2025